System of drug delivery to the lymphatic tissues
AssigneeThe General Hospital Corporation
InventorsMikhail I. Papisov, Thomas J. Brady
Life of this patent
Estimating the term…
Abstract
A substance for diagnosis or therapy of an animal. The substance includes an agent which is detectable or therapeutically active, the agent being linked to a carrier which is linked to a targeting site, whereby the agent accumulates in the lymphatic system of the animal to a greater degree than if the targeting site were absent.
Claims36
A method of delivering an agent to the lymph nodes of an animal by intravascular administration, the method comprising
- intravascularly administering to the animal a composition comprising (i) an organic inner core incorporating said agent, and (ii) an outer carbohydrate structure comprising a plurality of carbohydrate molecules grafted to said inner core;
- and
- allowing sufficient time for said composition to accumulate within the lymph nodes of the animal, wherein said composition has sufficient preference for lymph node tissue over liver tissue in a rat such that, 24 hours after intravascular injection of a dosage of 1 mg/kg body weight, the accumulated dose percent per gram of paraaortic and mesenteric lymph node tissue is greater than the accumulated dose percent per gram of liver tissue.
A composition that accumulates in the lymph nodes of an animal after intravascular administration, the composition comprising
- (i) an organic inner core, and
- (ii) an outer carbohydrate structure comprising a plurality of carbohydrate molecules grafted to said inner core,
- wherein said composition has sufficient preference for lymph node tissue over liver tissue in a rat such that, 24 hours after intravascular injection of a dosage of 1 mg/kg body weight, the accumulated dose percent per gram of paraaortic and mesenteric lymph node tissue is greater than the accumulated dose percent per gram of liver tissue.
A composition that accumulates in the lymph nodes of an animal after intravascular administration, the composition comprising
- (i) an inner core comprising one or more colloidal iron oxide particles, and
- (ii) a dense, outer carbohydrate structure comprising a plurality of carbohydrate molecules grafted to said inner core, said carbohydrate structure sterically protecting said inner core once said composition is administered to the animal,
- wherein said outer carbohydrate layer is grafted to said inner core during core formation by dissolving an iron salt in a solution of at least 5 percent, by weight, of said carbohydrate in water, cooling the resulting solution to about 4.degree. C., increasing the pH of the cooled solution to about 10.0, incubating the solution at about 70.degree. C., and separating said composition from the solution, and
- wherein said composition has sufficient preference for lymph node tissue over liver tissue in a rat such that, 24 hours after intravascular injection of a dosage of 1 mg/kg body weight, the accumulated dose percent per gram of paraaortic and mesenteric lymph node tissue is greater than the accumulated dose percent per gram of liver tissue.
A composition that accumulates in the lymph nodes of an animal after intravascular administration, the composition comprising
- (i) an inner core comprising one or more diamagnetic or paramagnetic colloidal particles, and
- (ii) a dense, outer carbohydrate structure comprising a plurality of carbohydrate molecules grafted to said inner core,
- wherein said composition has sufficient preference for lymph node tissue over liver tissue in a rat such that, 24 hours after intravascular injection of a dosage of 1 mg/kg body weight, the accumulated dose percent per gram of paraaortic and mesenteric lymph node tissue is greater than the accumulated dose percent per gram of liver tissue.
Dependencies are inferred from the claim text.